Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.
ADVANCED SEARCH
Log in
Top
Respiratory Research
Published in: Respiratory Research 1/2006

Open Access 01-12-2006 | Research

Expression of S100A8 correlates with inflammatory lung disease in congenic mice deficient of the cystic fibrosis transmembrane conductance regulator

Authors: Sam Tirkos, Susan Newbigging, Van Nguyen, Mary Keet, Cameron Ackerley, Geraldine Kent, Richard F Rozmahel

Published in: Respiratory Research | Issue 1/2006

Login to get access

Abstract

Background

Lung disease in cystic fibrosis (CF) patients is dominated by chronic inflammation with an early and inappropriate influx of neutrophils causing airway destruction. Congenic C57BL/6 CF mice develop lung inflammatory disease similar to that of patients. In contrast, lungs of congenic BALB/c CF mice remain unaffected. The basis of the neutrophil influx to the airways of CF patients and C57BL/6 mice, and its precipitating factor(s) (spontaneous or infection induced) remains unclear.

Methods

The lungs of 20-day old congenic C57BL/6 (before any overt signs of inflammation) and BALB/c CF mouse lines maintained in sterile environments were investigated for distinctions in the neutrophil chemokines S100A8 and S100A9 by quantitative RT-PCR and RNA in situ hybridization, that were then correlated to neutrophil numbers.

Results

The lungs of C57BL/6 CF mice had spontaneous and significant elevation of both neutrophil chemokines S100A8 and S100A9 and a corresponding increase in neutrophils, in the absence of detectable pathogens. In contrast, BALB/c CF mouse lungs maintained under identical conditions, had similar elevations of S100A9 expression and resident neutrophil numbers, but diverged in having normal levels of S100A8.

Conclusion

The results indicate early and spontaneous lung inflammation in CF mice, whose progression corresponds to increased expression of both S100A8 and S100A9, but not S100A9 alone. Moreover, since both C57BL/6 and BALB/c CF lungs were maintained under identical conditions and had similar elevations in S100A9 and neutrophils, the higher S100A8 expression in the former (or suppression in latter) is a result of secondary genetic influences rather than environment or differential infection.
Literature
1.
Rommens JM, Iannuzzi MC, Kerem B, Drumm ML, Melmer G, Dean M, Rozmahel R, Cole JL, Kennedy D, Hidaka N, Zsiga M, Buchwald M, Riordan J, Tsui L-C, Collins FS: Identification of the cystic fibrosis gene: chromosome walking and jumping. Science 1989,245(4922):1059–1065.PubMedCrossRef
2.
Riordan JR, Rommens J, Kerem B, Alon N, Rozmahel R, Grzelczak Z, Zielenski J, Lok S, Plavsic N, Chou J-L, Drumm M, Iannuzzi M, Collins SF, Tsui L-C: Identification of the cystic fibrosis gene: cloning and characterization of complementary DNA. Science 1989,245(4922):1066–1073.PubMedCrossRef
3.
Welsh MJ, Ramsey BW, Accurso FJ, Cutting GR, (ed): Cystic fibrosis. Eigth edition. New York, NY: McGraw-Hill Inc; 2001.
4.
5.
Muhlebach MS, Stewart PW, Leigh MW, Noah TL: Quantitation of inflammatory responses to bacteria in young cystic fibrosis and control patients. Am J Respir Crit Care Med 1999,160(1):186–191.PubMedCrossRef
6.
Konstan MW, Hilliard KA, Norvell TM, Berger M: Bronchoalveolar lavage findings in cystic fibrosis patients with stable, clinically mild lung disease suggest ongoing infection and inflammation. Am J Respir Crit Care Med 1994,150(2):448–454.PubMedCrossRef
7.
Konstan MW, Berger M: Current understanding of the inflammatory process in cystic fibrosis: onset and etiology. Pediatr Pulmonol 1997,24(2):137–142.PubMedCrossRef
8.
Balough K, McCubbin M, Weinberger M, Smits W, Ahrens R, Fick R: The relationship between infection and inflammation in the early stages of lung disease from cystic fibrosis. Pediatr Pulmonol 1995,20(2):63–70.PubMedCrossRef
9.
Khan TZ, Wagener JS, Bost T, Martinez J, Accurso FJ, Riches DW: Early pulmonary inflammation in infants with cystic fibrosis. Am J Respir Crit Care Med 1995,151(4):1075–1082.PubMed
10.
Bonfield TL, Konstan MW, Berger M: Altered respiratory epithelial cell cytokine production in cystic fibrosis. J Allergy Clin Immunol 1999,104(1):72–78.PubMedCrossRef
11.
Bonfield TL, Konstan MW, Burfeind P, Panuska JR, Hilliard JB, Berger M: Normal bronchial epithelial cells constitutively produce the anti-inflammatory cytokine interleukin-10, which is downregulated in cystic fibrosis. Am J Respir Cell Mol Biol 1995,13(3):257–261.PubMedCrossRef
12.
Bonfield TL, Panuska JR, Konstan MW, Hilliard KA, Hilliard JB, Ghnaim H, Berger M: Inflammatory cytokines in cystic fibrosis lungs. Am J Respir Crit Care Med 1995,152(6 Pt 1):2111–2118.PubMedCrossRef
13.
Massengale AR, Quinn F Jr, Yankaskas J, Weissman D, McClellan WT, Cuff C, Aronoff SC: Reduced interleukin-8 production by cystic fibrosis airway epithelial cells. Am J Respir Cell Mol Biol 1999,20(5):1073–1080.PubMedCrossRef
14.
Stecenko AA, King G, Torii K, Breyer RM, Dworski R, Blackwell TS, Christman JW, Brigham KL: Dysregulated cytokine production in human cystic fibrosis bronchial epithelial cells. Inflammation 2001,25(3):145–155.PubMedCrossRef
15.
Tabary O, Zahm JM, Hinnrasky J, Couetil JP, Cornillet P, Guenounou M, Gaillard D, Puchelle E, Jacquot J: Selective up-regulation of chemokine IL-8 expression in cystic fibrosis bronchial gland cells in vivo and in vitro. Am J Pathol 1998,153(3):921–930.PubMedPubMedCentralCrossRef
16.
Venkatakrishnan A, Stecenko AA, King G, Blackwell TR, Brigham KL, Christman JW, Blackwell TS: Exaggerated activation of nuclear factor-kappaB and altered IkappaB-beta processing in cystic fibrosis bronchial epithelial cells. Am J Respir Cell Mol Biol 2000,23(3):396–403.PubMedCrossRef
17.
Doring G, Worlitzsch D: Inflammation in cystic fibrosis and its management. Paediatr Respir Rev 2000,1(2):101–106.PubMed
18.
Kammouni W, Figarella C, Marchand S, Merten M: Altered cytokine production by cystic fibrosis tracheal gland serous cells. Infect Immun 1997,65(12):5176–5183.PubMedPubMedCentral
19.
Kube D, Sontich U, Fletcher D, Davis PB: Proinflammatory cytokine responses to P. aeruginosa infection in human airway epithelial cell lines. Am J Physiol Lung Cell Mol Physiol 2001,280(3):L493–502.PubMed
20.
Schwiebert LM, Estell K, Propst SM: Chemokine expression in CF epithelia: implications for the role of CFTR in RANTES expression. Am J Physiol 1999,276(3 Pt 1):C700–710.PubMed
21.
Rosenfeld M, Gibson RL, McNamara S, Emerson J, Burns JL, Castile R, Hiatt P, McCoy K, Wilson CB, Inglis A, Smith A, Martin TR, Ramsey BW: Early pulmonary infection, inflammation, and clinical outcomes in infants with cystic fibrosis. Pediatr Pulmonol 2001,32(5):356–366.PubMedCrossRef
22.
Armstrong DS, Grimwood K, Carzino R, Carlin JB, Olinsky A, Phelan PD: Lower respiratory infection and inflammation in infants with newly diagnosed cystic fibrosis. Bmj 1995,310(6994):1571–1572.PubMedPubMedCentralCrossRef
23.
Grubb BR, Paradiso AM, Boucher RC: Anomalies in ion transport in CF mouse tracheal epithelium. Am J Physiol 1994.
24.
Grubb BR, Vick RN, Boucher RC: Hyperabsorption of Na+ and raised Ca(2+)-mediated Cl-secretion in nasal epithelia of CF mice. Am J Physiol 1994.
25.
Scholte BJ, Davidson DJ, Wilke M, De Jonge HR: Animal models of cystic fibrosis. J Cyst Fibros 2004,3(Suppl 2):183–190.PubMedCrossRef
26.
Kent G, Iles R, Bear CE, Huan LJ, Griesenbach U, McKerlie C, Frndova H, Ackerley C, Gosselin D, Radzioch D, O'Brodovich H, Tsui LC, Buchwald M, Tanswell AK: Lung disease in mice with cystic fibrosis. J Clin Invest 1997,100(12):3060–3069.PubMedPubMedCentralCrossRef
27.
Haston CK, McKerlie C, Newbigging S, Corey M, Rozmahel R, Tsui LC: Detection of modifier loci influencing the lung phenotype of cystic fibrosis knockout mice. Mamm Genome 2002,13(11):605–613.PubMedCrossRef
28.
Durie PR, Kent G, Phillips MJ, Ackerley CA: Characteristic multiorgan pathology of cystic fibrosis in a long-living cystic fibrosis transmembrane regulator knockout murine model. Am J Pathol 2004,164(4):1481–1493.PubMedPubMedCentralCrossRef
29.
Heeckeren A, Walenga R, Konstan MW, Bonfield T, Davis PB, Ferkol T: Excessive inflammatory response of cystic fibrosis mice to bronchopulmonary infection with Pseudomonas aeruginosa. J Clin Invest 1997,100(11):2810–2815.PubMedPubMedCentralCrossRef
30.
Cowley EA, Wang CG, Gosselin D, Radzioch D, Eidelman DH: Mucociliary clearance in cystic fibrosis knockout mice infected with Pseudomonas aeruginosa. Eur Respir J 1997,10(10):2312–2318.PubMedCrossRef
31.
Thomas GR, Costelloe EA, Lunn DP, Stacey KJ, Delaney SJ, Passey R, McGlinn EC, McMorran BJ, Ahadizadeh A, Geczy CL, Wainwright BJ, Hume DA: G551D cystic fibrosis mice exhibit abnormal regulation of inflammation in lungs and macrophages. J Immunol 2000,164(7):3870–3877.PubMedCrossRef
32.
Davidson DJ, Dorin JR, McLachlan G, Ranaldi V, Lamb D, Doherty C, Govan J, Porteous DJ: Lung disease in the cystic fibrosis mouse exposed to bacterial pathogens. Nat Genet 1995,9(4):351–357.PubMedCrossRef
33.
Coleman FT, Mueschenborn S, Meluleni G, Ray C, Carey VJ, Vargas SO, Cannon CL, Ausubel FM, Pier GB: Hypersusceptibility of cystic fibrosis mice to chronic Pseudomonas aeruginosa oropharyngeal colonization and lung infection. Proc Natl Acad Sci U S A 2003,100(4):1949–1954.PubMedPubMedCentralCrossRef
34.
McMorran BJ, Palmer JS, Lunn DP, Oceandy D, Costelloe EO, Thomas GR, Hume DA, Wainwright BJ: G551D CF mice display an abnormal host response and have impaired clearance of Pseudomonas lung disease. Am J Physiol Lung Cell Mol Physiol 2001,281(3):L740–747.PubMed
35.
Sajjan U, Thanassoulis G, Cherapanov V, Lu A, Sjolin C, Steer B, Wu YJ, Rotstein OD, Kent G, McKerlie C, Forstner J, Downey GP: Enhanced susceptibility to pulmonary infection with Burkholderia cepacia in Cftr(-/-) mice. Infect Immun 2001,69(8):5138–5150.PubMedPubMedCentralCrossRef
36.
Guilbault C, Martin P, Houle D, Boghdady ML, Guiot MC, Marion D, Radzioch D: Cystic fibrosis lung disease following infection with Pseudomonas aeruginosa in Cftr knockout mice using novel non-invasive direct pulmonary infection technique. Lab Anim 2005,39(3):336–352.PubMedCrossRef
37.
Stotland PK, Radzioch D, Stevenson MM: Mouse models of chronic lung infection with pseudomonas aeruginosa: models for the study of cystic fibrosis. Pediatr Pulmonol 2000,30(5):413–424.PubMedCrossRef
38.
Xu Y, Clark JC, Aronow BJ, Dey CR, Liu C, Wooldridge JL, Whitsett JA: Transcriptional adaptation to cystic fibrosis transmembrane conductance regulator deficiency. J Biol Chem 2003,278(9):7674–7682.PubMedCrossRef
39.
Bensalem N, Ventura AP, Vallee B, Lipecka J, Tondelier D, Davezac N, Dos Santos A, Perretti M, Fajac A, Sermet-Gaudelus I, Renouil M, Lesure JF, Halgand F, Laprevote O, Edelman A: Down-regulation of the anti-inflammatory protein annexin A1 in cystic fibrosis knock-out mice and patients. Mol Cell Proteomics 2005,4(10):1591–1601.PubMedCrossRef
40.
Saadane A, Soltys J, Berger M: Role of IL-10 deficiency in excessive nuclear factor-kappaB activation and lung inflammation in cystic fibrosis transmembrane conductance regulator knockout mice. J Allergy Clin Immunol 2005,115(2):405–411.PubMedCrossRef
41.
Guilbault C, Novak JP, Martin P, Boghdady ML, Saeed Z, Guiot MC, Hudson TJ, Radzioch D: Distinct pattern of lung gene expression in the Cftr-KO mice developing spontaneous lung disease compared to their littermate controls. Physiol Genomics 2006.
42.
Kent G, Ackerley C: Personal communication. 2003.
43.
Tirkos S, Chung C, Fang I, Kent G, Rozmahel R: Investigation of S100A8 as a modifier of lung disease in CF mice. Pediatr Pulmonol 2001,32(S22):A299.
44.
Nacken W, Roth J, Sorg C, Kerkhoff C: S100A9/S100A8: Myeloid representatives of the S100 protein family as prominent players in innate immunity. Microsc Res Tech 2003,60(6):569–580.PubMedCrossRef
45.
Passey RJ, Xu K, Hume DA, Geczy CL: S100A8: emerging functions and regulation. J Leukoc Biol 1999,66(4):549–556.PubMed
46.
Ryckman C, Vandal K, Rouleau P, Talbot M, Tessier PA: Proinflammatory activities of S100: proteins S100A8, S100A9, and S100A8/A9 induce neutrophil chemotaxis and adhesion. J Immunol 2003,170(6):3233–3242.PubMedCrossRef
47.
Roth J, Vogl T, Sorg C, Sunderkotter C: Phagocyte-specific S100 proteins: a novel group of proinflammatory molecules. Trends Immunol 2003,24(4):155–158.PubMedCrossRef
48.
Thorey IS, Roth J, Regenbogen J, Halle JP, Bittner M, Vogl T, Kaesler S, Bugnon P, Reitmaier B, Durka S, Graf A, Wockner M, Rieger N, Konstantinow A, Wolf E, Goppelt A, Werner S: The Ca2+-binding proteins S100A8 and S100A9 are encoded by novel injury-regulated genes. J Biol Chem 2001,276(38):35818–35825.PubMedCrossRef
49.
Yui S, Nakatani Y, Mikami M: Calprotectin (S100A8/S100A9), an inflammatory protein complex from neutrophils with a broad apoptosis-inducing activity. Biol Pharm Bull 2003,26(6):753–760.PubMedCrossRef
50.
Foell D, Frosch M, Sorg C, Roth J: Phagocyte-specific calcium-binding S100 proteins as clinical laboratory markers of inflammation. Clin Chim Acta 2004,344(1–2):37–51.PubMedCrossRef
51.
Striz I, Trebichavsky I: Calprotectin – a pleiotropic molecule in acute and chronic inflammation. Physiol Res 2004,53(3):245–253.PubMed
52.
Haston CK, Tsui LC: Loci of intestinal distress in cystic fibrosis knockout mice. Physiol Genomics 2003,12(2):79–84.PubMedCrossRef
53.
Haston CK, Corey M, Tsui LC: Mapping of genetic factors influencing the weight of cystic fibrosis knockout mice. Mamm Genome 2002,13(11):614–618.PubMedCrossRef
54.
Kent G, Oliver M, Foskett JK, Frndova H, Durie P, Forstner J, Forstner GG, Riordan JR, Percy D, Buchwald M: Phenotypic abnormalities in long-term surviving cystic fibrosis mice. Pediatr Res 1996,40(2):233–241.PubMedCrossRef
55.
56.
Ravasi T, Hsu K, Goyette J, Schroder K, Yang Z, Rahimi F, Miranda LP, Alewood PF, Hume DA, Geczy C: Probing the S100 protein family through genomic and functional analysis. Genomics 2004,84(1):10–22.PubMedCrossRef
57.
Edgeworth J, Gorman M, Bennett R, Freemont P, Hogg N: Identification of p8,14 as a highly abundant heterodimeric calcium binding protein complex of myeloid cells. J Biol Chem 1991,266(12):7706–7713.PubMed
58.
Hessian PA, Edgeworth J, Hogg N: MRP-8 and MRP-14, two abundant Ca(2+)-binding proteins of neutrophils and monocytes. J Leukoc Biol 1993,53(2):197–204.PubMed
59.
Heizmann CW: The multifunctional S100 protein family. Methods Mol Biol 2002, 172:69–80.PubMed
60.
Hobbs JA, May R, Tanousis K, McNeill E, Mathies M, Gebhardt C, Henderson R, Robinson MJ, Hogg N: Myeloid cell function in MRP-14 (S100A9) null mice. Mol Cell Biol 2003,23(7):2564–2576.PubMedPubMedCentralCrossRef
61.
Kerkhoff C, Klempt M, Kaever V, Sorg C: The two calcium-binding proteins, S100A8 and S100A9, are involved in the metabolism of arachidonic acid in human neutrophils. J Biol Chem 1999,274(46):32672–32679.PubMedCrossRef
62.
Kerkhoff C, Sorg C, Tandon NN, Nacken W: Interaction of S100A8/S100A9-arachidonic acid complexes with the scavenger receptor CD36 may facilitate fatty acid uptake by endothelial cells. Biochemistry 2001,40(1):241–248.PubMedCrossRef
63.
Devery JM, King NJ, Geczy CL: Acute inflammatory activity of the S100 protein CP-10. Activation of neutrophils in vivo and in vitro. J Immunol 1994,152(4):1888–1897.PubMed
64.
Graf JM, Smith CW, Mariscalco MM: Contribution of LFA-1 and Mac-1 to CD18-dependent neutrophil emigration in a neonatal rabbit model. J Appl Physiol 1996,80(6):1984–1992.PubMed
65.
Smith CW, Marlin SD, Rothlein R, Toman C, Anderson DC: Cooperative interactions of LFA-1 and Mac-1 with intercellular adhesion molecule-1 in facilitating adherence and transendothelial migration of human neutrophils in vitro. J Clin Invest 1989,83(6):2008–2017.PubMedPubMedCentralCrossRef
66.
Eue I, Pietz B, Storck J, Klempt M, Sorg C: Transendothelial migration of 27E10+ human monocytes. Int Immunol 2000,12(11):1593–1604.PubMedCrossRef
67.
Roth J, Burwinkel F, van den Bos C, Goebeler M, Vollmer E, Sorg C: MRP8 and MRP14, S-100-like proteins associated with myeloid differentiation, are translocated to plasma membrane and intermediate filaments in a calcium-dependent manner. Blood 1993,82(6):1875–1883.PubMed
68.
Mahnke K, Bhardwaj R, Sorg C: Heterodimers of the calcium-binding proteins MRP8 and MRP14 are expressed on the surface of human monocytes upon adherence to fibronectin and collagen. Relation to TNF-alpha, IL-6, and superoxide production. J Leukoc Biol 1995,57(1):63–71.PubMed
69.
Newton RA, Hogg N: The human S100 protein MRP-14 is a novel activator of the beta 2 integrin Mac-1 on neutrophils. J Immunol 1998,160(3):1427–1435.PubMed
70.
Vandal K, Rouleau P, Boivin A, Ryckman C, Talbot M, Tessier PA: Blockade of S100A8 and S100A9 suppresses neutrophil migration in response to lipopolysaccharide. J Immunol 2003,171(5):2602–2609.PubMedCrossRef
71.
Steinbakk M, Naess-Andresen CF, Lingaas E, Dale I, Brandtzaeg P, Fagerhol MK: Antimicrobial actions of calcium binding leucocyte L1 protein, calprotectin. Lancet 1990,336(8718):763–765.PubMedCrossRef
72.
Sohnle PG, Collins-Lech C, Wiessner JH: Antimicrobial activity of an abundant calcium-binding protein in the cytoplasm of human neutrophils. J Infect Dis 1991,163(1):187–192.PubMedCrossRef
73.
Santhanagopalan V, Hahn BL, Sohnle PG: Resistance of zinc-supplemented Candida albicans cells to the growth inhibitory effect of calprotectin. J Infect Dis 1995,171(5):1289–1294.PubMedCrossRef
74.
Brandtzaeg P, Gabrielsen TO, Dale I, Muller F, Steinbakk M, Fagerhol MK: The leucocyte protein L1 (calprotectin): a putative nonspecific defence factor at epithelial surfaces. Adv Exp Med Biol 1995, 371A:201–206.PubMedCrossRef
75.
Sohnle PG, Hahn BL, Santhanagopalan V: Inhibition of Candida albicans growth by calprotectin in the absence of direct contact with the organisms. J Infect Dis 1996,174(6):1369–1372.PubMedCrossRef
76.
Loomans HJ, Hahn BL, Li QQ, Phadnis SH, Sohnle PG: Histidine-based zinc-binding sequences and the antimicrobial activity of calprotectin. J Infect Dis 1998,177(3):812–814.PubMedCrossRef
77.
Sohnle PG, Hunter MJ, Hahn B, Chazin WJ: Zinc-reversible antimicrobial activity of recombinant calprotectin (migration inhibitory factor-related proteins 8 and 14). J Infect Dis 2000,182(4):1272–1275.PubMedCrossRef
78.
Nisapakultorn K, Ross KF, Herzberg MC: Calprotectin expression in vitro by oral epithelial cells confers resistance to infection by Porphyromonas gingivalis. Infect Immun 2001,69(7):4242–4247.PubMedPubMedCentralCrossRef
79.
Nisapakultorn K, Ross KF, Herzberg MC: Calprotectin expression inhibits bacterial binding to mucosal epithelial cells. Infect Immun 2001,69(6):3692–3696.PubMedPubMedCentralCrossRef
80.
Passey RJ, Williams E, Lichanska AM, Wells C, Hu S, Geczy CL, Little MH, Hume DA: A null mutation in the inflammation-associated S100 protein S100A8 causes early resorption of the mouse embryo. J Immunol 1999,163(4):2209–2216.PubMed
81.
Pechkovsky DV, Zalutskaya OM, Ivanov GI, Misuno NI: Calprotectin (MRP8/14 protein complex) release during mycobacterial infection in vitro and in vivo. FEMS Immunol Med Microbiol 2000,29(1):27–33.PubMedCrossRef
82.
Barthe C, Carrere J, Figarella C, Guy-Crotte O: Isolation of the "cystic fibrosis protein" from serum. Clin Chem 1989,35(9):1901–1905.PubMed
83.
Barthe C, Figarella C, Carrere J, Guy CO: Identification of 'cystic fibrosis protein' as a complex of two calcium-binding proteins present in human cells of myeloid origin. Biochim Biophys Acta 1991,1096(2):175–177.PubMedCrossRef
84.
Roth J, Teigelkamp S, Wilke M, Grun L, Tummler B, Sorg C: Complex pattern of the myelo-monocytic differentiation antigens MRP8 and MRP14 during chronic airway inflammation. Immunobiology 1992,186(3–4):304–314.PubMedCrossRef
85.
Frosch M, Strey A, Vogl T, Wulffraat NM, Kuis W, Sunderkotter C, Harms E, Sorg C, Roth J: Myeloid-related proteins 8 and 14 are specifically secreted during interaction of phagocytes and activated endothelium and are useful markers for monitoring disease activity in pauciarticular-onset juvenile rheumatoid arthritis. Arthritis Rheum 2000,43(3):628–637.PubMedCrossRef
86.
Brun JG, Haga HJ, Boe E, Kallay I, Lekven C, Berntzen HB, Fagerhol MK: Calprotectin in patients with rheumatoid arthritis: relation to clinical and laboratory variables of disease activity. J Rheumatol 1992,19(6):859–862.PubMed
87.
Lugering N, Stoll R, Schmid KW, Kucharzik T, Stein H, Burmeister G, Sorg C, Domschke W: The myeloic related protein MRP8/14 (27E10 antigen) – usefulness as a potential marker for disease activity in ulcerative colitis and putative biological function. Eur J Clin Invest 1995,25(9):659–664.PubMedCrossRef
88.
Manitz MP, Horst B, Seeliger S, Strey A, Skryabin BV, Gunzer M, Frings W, Schonlau F, Roth J, Sorg C, Nacken W: Loss of S100A9 (MRP14) results in reduced interleukin-8-induced CD11b surface expression, a polarized microfilament system, and diminished responsiveness to chemoattractants in vitro. Mol Cell Biol 2003,23(3):1034–1043.PubMedPubMedCentralCrossRef
89.
Hu SP, Harrison C, Xu K, Cornish CJ, Geczy CL: Induction of the chemotactic S100 protein, CP-10, in monocyte/macrophages by lipopolysaccharide. Blood 1996,87(9):3919–3928.PubMed
90.
Xu K, Geczy CL: IFN-gamma and TNF regulate macrophage expression of the chemotactic S100 protein S100A8. J Immunol 2000,164(9):4916–4923.PubMedCrossRef
91.
Yen T, Harrison CA, Devery JM, Leong S, Iismaa SE, Yoshimura T, Geczy CL: Induction of the S100 chemotactic protein, CP-10, in murine microvascular endothelial cells by proinflammatory stimuli. Blood 1997,90(12):4812–4821.PubMed
Metadata
Title
Expression of S100A8 correlates with inflammatory lung disease in congenic mice deficient of the cystic fibrosis transmembrane conductance regulator
Authors
Sam Tirkos
Susan Newbigging
Van Nguyen
Mary Keet
Cameron Ackerley
Geraldine Kent
Richard F Rozmahel
Publication date
01-12-2006
Publisher
BioMed Central
Published in
Respiratory Research / Issue 1/2006
Electronic ISSN: 1465-993X
DOI
https://doi.org/10.1186/1465-9921-7-51

Other articles of this Issue 1/2006

Respiratory Research 1/2006 Go to the issue

Research

Cigarette smoke exposure facilitates allergic sensitization in mice

Research

Expression of eicosanoid receptors subtypes and eosinophilic inflammation: implication on chronic rhinosinusitis

Research

WFDC2 (HE4): A potential role in the innate immunity of the oral cavity and respiratory tract and the development of adenocarcinomas of the lung

Research

Activation of chloride transport in CF airway epithelial cell lines and primary CF nasal epithelial cells by S-nitrosoglutathione

Research

A self-rating scale for patient-perceived side effects of inhaled corticosteroids

Research

Allergens induce enhanced bronchoconstriction and leukotriene production in C5 deficient mice
Obesity Clinical Trial Summary

At a glance: The STEP trials

Read more

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Pediatric Cardiology Video

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

Cardiopulmonary Comorbidity Video

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Valvular Heart Disease Video

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Heart Failure Video

Watch this official video from ACC.24. Dr. Biykem Bozkurt discuss last year's major advances in heart failure and cardiomyopathies.

ACC 2024 Congress Coverage

Year in Review: Heart failure and cardiomyopathies

Heart Failure Video

Watch this official video from ACC.24. Dr. Biykem Bozkurt discuss last year's major advances in heart failure and cardiomyopathies.

Watch now

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

16-04-2024 Type 2 Diabetes News

Incentivised to exercise

11-04-2024 Lifestyle Modifications News

New intervention for STEMI-related cardiogenic shock

10-04-2024 Myocardial Infarction News

» View more highlights on the ACC 2024 congress hub page

Image Credits